|
1. |
A Possible New Approach to the Treatment ofNeuroleptic Malignant Syndrome |
|
Journal of Clinical Psychopharmacology,
Volume 12,
Issue 3,
1992,
Page 155-155
RICHARD SHADER,
DAVID GREENBLATT,
Preview
|
PDF (73KB)
|
|
ISSN:0271-0749
出版商:OVID
年代:1992
数据来源: OVID
|
2. |
A Double‐Blind, Placebo Controlled Study of Trazodonein Patients with Obsessive‐Compulsive Disorder |
|
Journal of Clinical Psychopharmacology,
Volume 12,
Issue 3,
1992,
Page 156-162
TERESA PIGOTT,
FRANCINE L'HEUREUX,
CHERYL RUBENSTEIN,
SUZANNE BERNSTEIN,
JAMES HILL,
DENNIS MURPHY,
Preview
|
PDF (646KB)
|
|
摘要:
Patients with obsessive-compulsive disorder (OCD) have been shown to be preferentially responsive to serotonin (5-HT) uptake-inhibiting antidepressants including clomipramine, fluoxetine, fluvoxamine, and sertraline. The nontricyclic antidepressant, trazodone, also possesses serotonin reuptake inhibiting properties and has been reported to be efficacious in OCD in several case reports and open trials. In order to investigate trazodone's potential antiobsessive efficacy in a controlled fashion, 21 patients with OCD were entered into a double-blind, parallel design comparison of trazodone and placebo. There were no significant differences in baseline rating scores of OCD or depressive symptoms between those who entered the trazodone phase (N = 13) versus those who entered the placebo phase (N = 8). As measured by standardized OCD and depression rating scales, there was no significant difference in OCD or depressive symptoms in the 17 patients who completed 10 weeks of trazodone (N = 11, mean daily dose, 235 ± 10 mg) versus 10 weeks of placebo (N = 6) administration. In comparison to clomipramine and fluoxetine treatment which we have found to be associated with > 95% reduction in platelet 5-HT concentration, there was only a 26% mean reduction in platelet 5-HT concentration after 10 weeks of trazodone administration. These results indicate that trazodone lacks substantial antiobsessive effects and is associated with only modest reductions in platelet 5-HT concentrations.
ISSN:0271-0749
出版商:OVID
年代:1992
数据来源: OVID
|
3. |
Increased Pulse and Blood Pressure Associated withDesipramine Treatment of Bulimia Nervosa |
|
Journal of Clinical Psychopharmacology,
Volume 12,
Issue 3,
1992,
Page 163-168
B. WALSH,
COLLEEN HADIGAN,
LINDA WONG,
Preview
|
PDF (580KB)
|
|
摘要:
The cardiovascular effects of desipramine were assessed in 74 young women with bulimia nervosa participating in a 6-week double-blind, placebocontrolled study. Desipramine treatment was associated with significant increases in pulse, reclining systolic and diastolic blood pressures, and orthostatic hypotension. These effects were clearly evident in the first week of treatment and remained relatively unchanged during the subsequent 5 weeks. The mean increases in reclining systolic and diastolic pressures were approximately 10 mm Hg. Data from 16 patients treated for an additional 2 months indicated that most of the effects of desipramine on blood pressure diminished over time, whereas the effects on pulse persisted. These results differ from the commonly expected cardiovascular effects of tricyclic antidepressants in adults. Evidence from the current study and from other reports suggests that the cardiovascular effects of tricyclic antidepressants are age-dependent.
ISSN:0271-0749
出版商:OVID
年代:1992
数据来源: OVID
|
4. |
Haloperidol Metabolism in Psychiatric PatientsImportance of Glucuronidation and Carbonyl Reduction |
|
Journal of Clinical Psychopharmacology,
Volume 12,
Issue 3,
1992,
Page 169-174
TOSHIYUKI SOMEYA,
MORIKAZU SHIBASAKI,
TOSHIFUMI NOGUCHI,
SABURO TAKAHASHI,
TADANOBU INABA,
Preview
|
PDF (448KB)
|
|
摘要:
In 39 patients who received haloperidol regularly we measured plasma concentrations of haloperidol glucuronide (HAL-GL), reduced haloperidol glucuronide (RHAL-GL), haloperidol (HAL), reduced haloperidol (RHAL), and HAL reductase activity in red blood cells. Plasma HAL-GL concentrations were significantly higher than HAL, RHAL, or RHAL-GL concentrations. Concentration ratios of total glucuronide to nonglucuronide and RHAL/HAL ratios were calculated as indices of glucuronidation and reduction capacity in each patient. The plasma glucuronidation ratios showed a significant negative correlation (r= −0.63,p< 0.001) with the dose, while the reduction ratios showed a positive correlation (r= 0.75,p< 0.001). No correlations were found between the HAL reductase activity in red blood cells and either the dose or RHAL/HAL. Based on these findings we suggest that glucuronidation of HAL is the major metabolic pathway of HAL in humans and its activity is important in determining steady-state plasma HAL concentrations. Glucuronidation may also be a major contributing factor in the interindividual variability of HAL metabolism.
ISSN:0271-0749
出版商:OVID
年代:1992
数据来源: OVID
|
5. |
A Double‐Blind Clinical Trial of Alprazolam,Imipramine, or Placebo in the Depressed Elderly |
|
Journal of Clinical Psychopharmacology,
Volume 12,
Issue 3,
1992,
Page 175-182
MYRNA WEISSMAN,
BRIGITTE PRUSOFF,
ALAN SHOLOMSKAS,
STEVEN GREENWALD,
Preview
|
PDF (731KB)
|
|
摘要:
The efficacy and safety of alprazolam as compared to imipramine or a placebo added to weekly interpersonal psychotherapy was compared in a 6-week double-blind randomized clinical trial of 35 ambulatory elderly patients with major depression. The average maximum dosage of alprazolam was 2.2 mg and the average maximum dosage of imipramine was 97.5 mg. The findings showed a rapid onset of action of alprazolam within 1 week on symptoms of depression and anxiety. The effects for imipramine were seen later in the study. There were no serious side effects that interfered with treatment. The anticholinergic effects of imipramine were the ones that most commonly interfered with treatment. Alprazolam produced the greatest number of symptoms with discontinuation, most of which were alleviated within a week. We conclude that alprazolam may be useful as an antidepressant for the elderly. More clinical trials are needed to test its efficacy in the depressed elderly with concomitant medical problems, using plasma levels. A double-blind discontinuation study of alprazolam is needed to determine the degree of symptom return.
ISSN:0271-0749
出版商:OVID
年代:1992
数据来源: OVID
|
6. |
Nitrazepam Clearance Unimpaired in Patients withRenal Insufficiency |
|
Journal of Clinical Psychopharmacology,
Volume 12,
Issue 3,
1992,
Page 183-185
HERMANN OCHS,
UDO OBEREM,
DAVID GREENBLATT,
Preview
|
PDF (255KB)
|
|
摘要:
Eight patients with mild to moderate renal insufficiency (mean serum creatinine: 2.4 mg/100 ml) and 9 matched control subjects with normal renal function received a single 5-mg oral dose of nitrazepam, cleared mainly by hepatic nitroreduction. Serum nitrazepam levels were determined by gas chromatography during the 72 hours after dosage. Renal patients and controls were well-matched for age (74 vs. 63 years), height (165 vs. 164 cm), and weight (68 vs. 64 kg). Patients and control subjects did not differ significantly in nitrazepam elimination half-life (32 vs. 24 hour) or volume of distribution (4.2 vs. 3.6 liters/kg). Clearance was higher in patients than in controls (4.2 vs. 1.7 ml/min/kg), but the difference was not significant. Nitrazepam free fraction in serum was increased in renal patients (16.8 vs. 15.0% unbound,p= 0.08). After correction for individual values of free fraction, the two groups still did not differ in kinetic variables for nitrazepam. Thus, mild to moderate renal insufficiency does not alter the kinetics of nitrazepam.
ISSN:0271-0749
出版商:OVID
年代:1992
数据来源: OVID
|
7. |
Haloperidol and Reduced Haloperidol inSaliva and Blood |
|
Journal of Clinical Psychopharmacology,
Volume 12,
Issue 3,
1992,
Page 186-190
M. DYSKEN,
S. JOHNSON,
L. HOLDEN,
M. KUSKOWSKI,
J. OFSTEHAGE,
STACY SKARE,
G. VATASSERY,
Preview
|
PDF (408KB)
|
|
摘要:
A total of 18 outpatients (17 male, 1 female) ranging in age from 36–66 years old were on a constant dosage of haloperidol in equally divided doses at 9:00 a.m. and 9:00 p.m. for at least 1 month. DSM-III-R diagnoses included schizophrenia (N = 9), schizoaffective disorder (N = 3), bipolar disorder (N = 4), organic mental disorder (N = 1), and delusional disorder (N = 1). Blood samples for steady-state concentrations of plasma and red blood cell haloperidol (H) and reduced haloperidol (RH) were drawn at 9:00 a.m. (12 hr trough). The haloperidol dosage was held at 9:00 a.m. until samples of whole saliva and parotid saliva could be collected for flow rates and concentrations of H and RH. Haloperidol dosages ranged from 1 mg/day to 60 mg/day (mean 11 ± 15). Correlation coefficients were calculated for saliva concentrations versus blood levels and for saliva secretion rates versus blood levels. The correlations between whole saliva measures and blood concentrations were all higher than the correlations between parotid saliva measures and blood concentrations. In one case the higher correlation reached statistical significance. There was only one case in which substitution of saliva secretion rate improved the correlation between measures with saliva concentration. Our findings suggest that saliva measures of H and RH are useful alternatives to plasma concentrations in monitoring maintenance haloperidol treatment.
ISSN:0271-0749
出版商:OVID
年代:1992
数据来源: OVID
|
8. |
A Longitudinal Evaluation ofDexamethasone Pharmacokinetics inDepressed Patients and Normal Controls |
|
Journal of Clinical Psychopharmacology,
Volume 12,
Issue 3,
1992,
Page 191-196
SALLY GUTHRIE,
MICHAEL HEIDT,
ATUL PANDE,
LEON GRUNHAUS,
ROGER HASKETT,
M. HARIHARAN,
Preview
|
PDF (557KB)
|
|
摘要:
Ten depressed patients and eight control subjects received 1 mg of dexamethasone intravenously at two different time points. Depressed patients were studied when they were depressed and following an improvement in their depression. In control subjects the first and second studies were performed approximately 1 month apart. Dexamethasone and cortisol were determined at 0, 5, 15, and 30 minutes, then at 1, 1.2, 2, 3, 4, 5, 6, 7, 9, 12, 17, and 24 hours following dexamethasone administration. Data from each patient was fit using a computer to a two compartment pharmacokinetic model and area under the time versus plasma concentration curve, elimination half-life, and clearance were also determined. Depressed patients exhibited a slower dexamethasone clearance and a larger area under the curve than control subjects at the first time point, but not at the second time point. The groups did not differ significantly in any of the other pharmacokinetic parameters (including distribution half-life, elimination half-life, or volume of distribution) at either time point. The possible causes and implications of these findings are discussed.
ISSN:0271-0749
出版商:OVID
年代:1992
数据来源: OVID
|
9. |
Predictive Value of Symptoms of Atypical Depressionfor Differential Drug Treatment Outcome |
|
Journal of Clinical Psychopharmacology,
Volume 12,
Issue 3,
1992,
Page 197-202
PATRICK MCGRATH,
JONATHAN STEWART,
WILMA HARRISON,
KATJA OCEPEK-WELIKSON,
JUDITH RABKIN,
EDWARD NUNES,
STEVEN WAGER,
ELAINE TRICAMO,
FREDERIC QUITKIN,
DONALD KLEIN,
Preview
|
PDF (499KB)
|
|
摘要:
Data for 401 depressed outpatients with mood reactivity who participated in a randomized trial comparing placebo, imipramine, and phenelzine were analyzed for predictors of differential response by stepwise multiple regression techniques. Features of the Columbia criteria for atypical depression including oversleeping, overeating, severe anergy, and pathologic rejection sensitivity were each predictive of a poorer response to imipramine than to phenelzineonlywhen compared to those patients with none of the features. These features were not additive in their contribution to differential outcome. Lack of endogenous features was not predictive of a differential drug treatment response. Compared with patients who have no symptoms of atypical depression, patients with any of the four features had an inferior imipramine response rather than a superior phenelzine response. These analyses indicate that the clear differential responsivity to medication treatment in atypical depression is not simply related to any one defining symptom and that further correlates of this apparent biological heterogeneity need to be explored.
ISSN:0271-0749
出版商:OVID
年代:1992
数据来源: OVID
|
10. |
Use of Drug Combinations in Treatmentof Opioid Withdrawal |
|
Journal of Clinical Psychopharmacology,
Volume 12,
Issue 3,
1992,
Page 203-209
SUSAN STINE,
THOMAS KOSTEN,
CATHERINE WALSH,
Preview
|
PDF (724KB)
|
|
摘要:
During the last 10 years new approaches for rapid opioid detoxification have included drug combinations such as clonidine and naltrexone to speed and ease the transition from opioid agonist to antagonist maintenance. Other drug combinations include naloxone with midazolam or methohexitone for inpatients, but rapid outpatient methods are more desirable. Clonidine combined with naltrexone enables abrupt opioid withdrawal in 3–5 days in an outpatient/day setting. This approach can be further improved by transition to the partial agonist buprenorphine from either heroin or methadone followed by a 1 day detoxification using naltrexone precipitated withdrawal, ameliorated by clonidine.
ISSN:0271-0749
出版商:OVID
年代:1992
数据来源: OVID
|
|